BACKGROUND: To determine the effects of patient demographics, socioeconomic status (SES) and clinical variables on outcomes for patients with salivary and parotid gland tumors. METHODS: Florida cancer registry and inpatient hospital data were queried for cancer of the salivary glands diagnosed between 1998-2002. RESULTS: A total of 1573 patients were identified. Women were diagnosed at a younger age (median age (years): women 60.8 versus men 64.3, P=0.003). Men were more often diagnosed with high grade tumors (65.1% versus 41.9% for women, P<0.001) and advanced disease stage (>stage III: 60.2 versus 49.4%, P<0.001), but underwent surgical extirpation and received radiation at equal rates compared with women. Overall 5-year survival rates was superior in women (67.4% versus 55.6%, P=0.001). By multivariate analysis, adjusted for patient comorbidities, age over 65 (HR 3.43 P=0.008), advanced disease stage (HR 8.05 P<0.001), and high tumor grade (HR 2.33, P<0.001) were independent predictors of worse prognosis. Improved outcomes were observed for female gender (HR 0.68, P=0.011). Tumors located in the parotid gland (HR 0.631 P=0.003) and receiving both surgical extirpation and radiation were predictors of improved survival. CONCLUSION: Salivary gland tumors carry a worse prognosis than tumors of the parotid. Male patients have worse outcomes.
BACKGROUND: To determine the effects of patient demographics, socioeconomic status (SES) and clinical variables on outcomes for patients with salivary and parotid gland tumors. METHODS: Florida cancer registry and inpatient hospital data were queried for cancer of the salivary glands diagnosed between 1998-2002. RESULTS: A total of 1573 patients were identified. Women were diagnosed at a younger age (median age (years): women 60.8 versus men 64.3, P=0.003). Men were more often diagnosed with high grade tumors (65.1% versus 41.9% for women, P<0.001) and advanced disease stage (>stage III: 60.2 versus 49.4%, P<0.001), but underwent surgical extirpation and received radiation at equal rates compared with women. Overall 5-year survival rates was superior in women (67.4% versus 55.6%, P=0.001). By multivariate analysis, adjusted for patient comorbidities, age over 65 (HR 3.43 P=0.008), advanced disease stage (HR 8.05 P<0.001), and high tumor grade (HR 2.33, P<0.001) were independent predictors of worse prognosis. Improved outcomes were observed for female gender (HR 0.68, P=0.011). Tumors located in the parotid gland (HR 0.631 P=0.003) and receiving both surgical extirpation and radiation were predictors of improved survival. CONCLUSION:Salivary gland tumors carry a worse prognosis than tumors of the parotid. Male patients have worse outcomes.
Authors: Ximena Mimica; Marlena McGill; Ashley Hay; Daniella Karassawa Zanoni; Jatin P Shah; Richard J Wong; Alan L Ho; Marc A Cohen; Snehal G Patel; Ian Ganly Journal: Oral Oncol Date: 2019-05-22 Impact factor: 5.337
Authors: Zachary C Taylor; Erin A Kaya; Jeffrey D Bunn; Zachary D Guss; Brian J Mitchell; Robert K Fairbanks; Wayne T Lamoreaux; Aaron E Wagner; Ben J Peressini; Christopher M Lee Journal: World J Clin Oncol Date: 2020-12-24
Authors: Joseph L Russell; Nai-Wei Chen; Shani J Ortiz; Travis P Schrank; Yong-Fang Kuo; Vicente A Resto Journal: JAMA Otolaryngol Head Neck Surg Date: 2014-06 Impact factor: 6.223
Authors: Eva Kristine Ruud Kjær; Jakob Schmidt Jensen; Kathrine Kronberg Jakobsen; Giedrius Lelkaitis; Irene Wessel; Christian von Buchwald; Christian Grønhøj Journal: Front Oncol Date: 2021-02-17 Impact factor: 6.244
Authors: Osias Vieira de Oliveira Filho; Talita Jordânia Rocha do Rêgo; Felipe Herbert de Oliveira Mendes; Thinali Sousa Dantas; Maria do Perpétuo Socorro Saldanha Cunha; Cássia Emanuella Nóbrega Malta; Paulo Goberlânio de Barros Silva; Fabrício Bitu Sousa Journal: Braz J Otorhinolaryngol Date: 2020-08-04